Pay attention to Canndoc, a research company very
Post# of 4861
(Total Views: 254)
Posted On: 05/26/2020 10:28:51 AM
Pay attention to Canndoc, a research company very involved in cannabis clinical trials. Canndoc imported the first ever cannabis product from Tilray, Portugal --- I reported this development back in March on the Univec board.
Canndoc has been pioneering Pharma-Grade cannabis for more than 12 years. Over the years, Canndoc provided more than 750,000 doses to 20,000 patients, establishing its position as a venerable player in this global industry, demonstrating significant expertise across the entire value chain from research, cultivation, and processing, to product development and advanced GMP clinical trials pipeline initiation.
Driven by the mission of meeting patients’ needs and improving their quality of life, Canndoc holds product efficacy to be of paramount importance, delivering Good Manufacturing Practice (GMP) pharma-grade cannabis solutions to achieve better patient health and treatment outcomes.
Canndoc's pharma grade cannabis products to be sold at Super-Pharm, Israel's leading and largest drugstore chain
HERZLIYA, Israel, March 5, 2020 /PRNewswire/ --- InterCure (TASE: INCR) announces today that wholly owned subsidiary, Canndoc, has entered into a strategic partnership agreement with Super-Pharm, Israel's leading and largest drugstore chain. Under the term of the agreement, Super-Pharm commits to acquire 10 tons of Canndoc's GMP medical cannabis products during a 3-year period. Canndoc's products will be securely transferred from its manufacturing facilities array to Super-Pharm's distribution center, who will be responsible for the distribution to its 41 medical cannabis authorized pharmacies.
"We are looking to provide our patients with the best service and highest quality to meet the growing demands for medical cannabis products," said Super-Pharm Chief Executive Officer Nitzan Lavi. "I welcome the strategic partnership with Canndoc which will enable us to increase our GMP standard medical cannabis inventory."
"We are honored to partner with Super-Pharm, Israel's leading drugstore chain," said Canndoc's Chief Executive Officer Alon Granot. "The collaboration between Super-Pharm and Canndoc supports the growing medical cannabis patients' community in Israel with access to our first-in-class medical cannabis products through the nationwide drugstore chain of Super-Pharm. This is another significant milestone in Canndoc's growth strategy."
Moshe Gavrilov, recently joined the Board of Canndoc after 18 years in senior management positions at Teva Pharmaceutical industries, said: "This is a significant achievement which positions Canndoc as the leading company in the growing GMP standard medical cannabis."
As part of the partnership, Canndoc will provide Super-Pharm and its pharmacists with professional and clinical expertise gained throughout its 12 years of development and treatment thousands of patients with medical cannabis. Canndoc will begin supplying its products to Super-Pharm immediately.
Yesterday, March 4, Canndoc announced a strategic pharma grade cannabis commercial deal with Cellect Biotechnology (NASDAQ: APOP), for the reduction of opioid usage. Canndoc and Cellect also announced the companies are exploring a potential merger. Canndoc intends to market the Canndoc-Cellect pharma grade cannabis products via its distribution channels including the Super-Pharm's strategic agreement.
https://www.canndoc-pharma.com/#Updates
Canndoc has been pioneering Pharma-Grade cannabis for more than 12 years. Over the years, Canndoc provided more than 750,000 doses to 20,000 patients, establishing its position as a venerable player in this global industry, demonstrating significant expertise across the entire value chain from research, cultivation, and processing, to product development and advanced GMP clinical trials pipeline initiation.
Driven by the mission of meeting patients’ needs and improving their quality of life, Canndoc holds product efficacy to be of paramount importance, delivering Good Manufacturing Practice (GMP) pharma-grade cannabis solutions to achieve better patient health and treatment outcomes.
Canndoc's pharma grade cannabis products to be sold at Super-Pharm, Israel's leading and largest drugstore chain
HERZLIYA, Israel, March 5, 2020 /PRNewswire/ --- InterCure (TASE: INCR) announces today that wholly owned subsidiary, Canndoc, has entered into a strategic partnership agreement with Super-Pharm, Israel's leading and largest drugstore chain. Under the term of the agreement, Super-Pharm commits to acquire 10 tons of Canndoc's GMP medical cannabis products during a 3-year period. Canndoc's products will be securely transferred from its manufacturing facilities array to Super-Pharm's distribution center, who will be responsible for the distribution to its 41 medical cannabis authorized pharmacies.
"We are looking to provide our patients with the best service and highest quality to meet the growing demands for medical cannabis products," said Super-Pharm Chief Executive Officer Nitzan Lavi. "I welcome the strategic partnership with Canndoc which will enable us to increase our GMP standard medical cannabis inventory."
"We are honored to partner with Super-Pharm, Israel's leading drugstore chain," said Canndoc's Chief Executive Officer Alon Granot. "The collaboration between Super-Pharm and Canndoc supports the growing medical cannabis patients' community in Israel with access to our first-in-class medical cannabis products through the nationwide drugstore chain of Super-Pharm. This is another significant milestone in Canndoc's growth strategy."
Moshe Gavrilov, recently joined the Board of Canndoc after 18 years in senior management positions at Teva Pharmaceutical industries, said: "This is a significant achievement which positions Canndoc as the leading company in the growing GMP standard medical cannabis."
As part of the partnership, Canndoc will provide Super-Pharm and its pharmacists with professional and clinical expertise gained throughout its 12 years of development and treatment thousands of patients with medical cannabis. Canndoc will begin supplying its products to Super-Pharm immediately.
Yesterday, March 4, Canndoc announced a strategic pharma grade cannabis commercial deal with Cellect Biotechnology (NASDAQ: APOP), for the reduction of opioid usage. Canndoc and Cellect also announced the companies are exploring a potential merger. Canndoc intends to market the Canndoc-Cellect pharma grade cannabis products via its distribution channels including the Super-Pharm's strategic agreement.
https://www.canndoc-pharma.com/#Updates
(2)
(0)Scroll down for more posts ▼